In 2001, Ludwig Cancer Research teamed up with the Cancer Research Institute (CRI) to create a centralized, coordinated, integrated network of clinical trial sites with expertise in immunological monitoring called the Cancer Vaccine Collaborative (CVC). This relationship evolved as the Anna-Maria Kellen Clinical Accelerator was established, and continues to produce unique cancer immunotherapy clinical trials that may have otherwise not been possible. Clinical trial management provided by Ludwig complements CRI’s history, expertise, and connections in the IO field to study novel combinations that may advance patient care and scientific breakthroughs.
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for 50 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested nearly $3 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers.